Trial Profile
A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2022
Price :
$35
*
At a glance
- Drugs Catridecacog (Primary)
- Indications Factor XIII deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 18 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2016 New trial record